BioXcel Therapeutics (BTAI) Reports Q4 Loss of $0.87/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
March 11, 2021 7:15 AM ESTNew Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) for BXCL501 for the acute treatment of schizophrenia and bipolar disorder related agitation
TRANQUILITY achieved primary and secondary endpoints with both doses of BXCL501; End of Phase 2 meeting with the FDA planned for Q2 2021
RELEASE trial on track to report topline results in Q1 2021
Topline results from two ongoing trials with BXCL701 in aggressive forms of prostate cancer and advanced solid tumors are expected in mid-2021
Company... More
